Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Keros Therapeutics ( (KROS) ) just unveiled an announcement.
On August 6, 2025, Keros Therapeutics announced a strategic realignment to focus on the development of its key clinical program, KER-065, while discontinuing the development of cibotercept. This decision follows the analysis of safety and efficacy data from the TROPOS Phase 2 clinical trial in pulmonary arterial hypertension. The company also announced several leadership changes, including the promotion of Lorena Lerner to Chief Scientific Officer and the appointment of Jean-Jacques Bienaimé as Chair of the Board. These changes aim to streamline operations and support Keros’ focus on advancing KER-065, which has shown promising results in a Phase 1 clinical trial and is expected to enter Phase 2 trials for Duchenne muscular dystrophy in early 2026.
The most recent analyst rating on (KROS) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
The overall score reflects a company in transition, with significant growth potential but also facing challenges typical of biotech firms. The financial performance and reliance on external funding are critical concerns, while recent corporate events highlight both progress and strategic challenges. Technical indicators offer some positive momentum, but valuation remains a key risk factor.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of these proteins, which regulate the growth, repair, and maintenance of various tissues. Keros’ lead product candidate, KER-065, is being developed for the treatment of neuromuscular diseases, with a focus on Duchenne muscular dystrophy.
Average Trading Volume: 575,238
Technical Sentiment Signal: Sell
Current Market Cap: $584.5M
For detailed information about KROS stock, go to TipRanks’ Stock Analysis page.